All tested patients were classified into two groups, Group A (patients who were tested positive) and Group B (patients who were tested negative). A total of 28 patients were evaluated. The primary diagnosis of patients in Group A was B-Cell ALL and Thalassemia Major (50% each), whereas, in Group B, the primary diagnosis was B-Cell ALL (46.1%) and AML. The most prevalent symptoms warranting testing in Group A were fever (100%) and cough (50%); Group B the most common symptoms were fever (53.8%), cough (26.9%), and neutropenia (15.4%). No mortality or significant morbidity was reported in either of the cohorts.